Aviado · Research
Longevity Daily
Wednesday, August 12, 2026
Listen
Today's Brief
Prevention dominates today: a long-term study in Neurology Open Access finds that controlling blood pressure, diabetes, and smoking in midlife buys 13 extra dementia-free years — our must-read and one of the most actionable longevity findings in months. A clinical trial also tests PD-L1 immune checkpoint antibodies — the same class used in cancer — to quiet brain inflammation in Alzheimer's disease. The XPRIZE Healthspan competition's top 10 finalists reveal the audacious multi-drug stacks leading longevity teams are betting on, while Medscape puts the wellness peptide trend under a skeptical lens.
10 stories1 peer-reviewed1 trials1 Aviado original
Cognitive Health & Neuroprotection
Avoiding Three Vascular Risk Factors in Midlife Buys You 13 Extra Dementia-Free Years
A long-term study published in Neurology Open Access found that people who avoided high blood pressure, diabetes, and smoking in middle age had approximately 13 more dementia-free years than those with all three risk factors — with hazard ratios of 2.69 for dementia and 5.61 for death without dementia in the highest-burden group. Dementia-free survival years shrank from 30.1 to 17.5 years as vascular risk burden increased, a gap that dwarfs most pharmaceutical interventions currently in development. If you're in your 40s or 50s, these three modifiable factors are your most powerful levers for protecting future cognitive function. The interventions required — blood pressure control, blood sugar management, and quitting smoking — are not exotic; they are accessible to most people willing to act now.
Read more →Clinical Trial Tests Cancer Immunotherapy Antibodies to Fight Alzheimer's Brain Inflammation
Trial results covered by Fight Aging! explore whether PD-L1 antibodies — immune checkpoint inhibitors best known from oncology — can reduce the chronic neuroinflammation that drives Alzheimer's progression. The approach targets a root cause rather than downstream amyloid plaques: aging microglia and other immune cells that sustain a destructive inflammatory environment in the brain. If validated in larger trials, this strategy could offer a complementary pathway to existing amyloid-targeting drugs.
Read more →Supplements & Compounds
Wellness Peptides Are Everywhere — But the Safety Data Isn't
Peptides like BPC-157 and TB-500 are flooding longevity forums and gym communities, with suppliers promising dramatic anti-aging and healing results. Medscape flags the reality: most wellness peptides have limited or no clinical evidence in humans, and the regulatory landscape allows bold marketing claims with minimal accountability. Before adding any peptide to your protocol, understand that you are largely running an uncontrolled self-experiment — know the risks.
Read more →A Daily Multivitamin May Help Older Adults Stay Independent Longer — But Read the Fine Print
A pre-print (not yet peer-reviewed) study suggests daily multivitamin use is associated with better physical functioning in older adults, with the strongest benefits seen in people with existing cardiovascular conditions like carotid stenosis — where gains reached clinically meaningful thresholds, not just statistical blips. The improvements were not uniform across all participants, and the research has not cleared peer review. Treat this as a promising early signal, not a reason to overhaul your supplement routine.
Read more →Aviado Research: Latest Evidence Review Now Available
Aviado Research has published an updated evidence-based review examining the latest findings in longevity science. Read the full analysis for Aviado's assessment of what the current research actually supports — and where hype still outpaces data.
Read the full Aviado analysis →Research & Papers
Why Biological Age Clocks Still Can't Tell You If Your Protocol Is Working
Aging clocks — epigenetic, proteomic, and beyond — promise to reveal your body's true biological age. But Fight Aging! surfaces a fundamental problem: until these clocks are calibrated against actual lifespan data, their readings cannot reliably assess whether any given intervention is working, which defeats their core purpose. For anyone using a commercial biological age test to evaluate supplements or lifestyle protocols, the numbers may be far more ambiguous than the marketing suggests.
Read more →XPRIZE Healthspan's Top 10 Finalists Reveal the Multi-Drug Stacks Leading Longevity Teams Are Betting On
The XPRIZE Healthspan competition's top 10 finalists are now public — and their protocols offer a rare window into the leading edge of longevity medicine. AgelessRx, for example, stacks rapamycin, low-dose naltrexone, metformin, NAD+, glutathione, sermorelin, and tirzepatide alongside resistance training, targeting multiple aging pathways simultaneously. These aren't individual supplements chosen casually — they're coordinated, physician-supervised multi-pathway interventions that represent the field's current best thinking on meaningfully extending human healthspan.
Read more →Lifestyle & Nutrition
Eating Less Protein May Support Longevity — But Your Optimal Intake Depends on Your Age
New research covered by Healthline suggests that lower protein intake may support healthy aging and longevity, adding meaningful nuance to the high-protein narrative that dominates fitness culture. The key caveat: the potential benefits appear age-dependent, meaning the right protein level for a 35-year-old building muscle may differ substantially from what a 70-year-old needs for long-term health. If you're optimizing for longevity as well as performance, it may be worth revisiting your protein targets as you age.
Read more →Industry & Policy
FDA Approves World's First mRNA Influenza Vaccine for Adults 50 and Older
Moderna's mFlusiva has received FDA approval as the first-ever mRNA-based influenza vaccine — approved for adults 50 and older, with accelerated approval for those 65 and above. Built on the same platform technology behind highly effective COVID-19 vaccines, mFlusiva brings a more adaptive, faster-to-update approach to flu prevention in the population most vulnerable to severe outcomes. For the aging adults our readers track, this is a significant advance in annual infectious disease risk management.
Read more →FDA Backs Second Drug for Extending Healthy Lifespan in Dogs — a Signal for Human Longevity Research
The FDA has determined that a second novel drug targeting healthy lifespan extension in large dogs has a 'reasonable expectation of effectiveness' — its clearest regulatory signal yet of openness to geroprotective drugs. Dog longevity trials are increasingly viewed as a critical translational bridge: dogs share our environment, age on a compressed timeline, and develop many of the same age-related conditions we do. What earns regulatory backing in canine longevity science often shapes the research agenda for human trials next.
Read more →